Dishman Pharma Q2 net profit surges near two fold to Rs 55 cr
New Delhi : Dishman Pharmaceuticals and Chemicals reported a near two-fold jump in consolidated net profit to Rs 54.68 crore for the second quarter ended September 30, mainly on account of robust sales in contract research and manufacturing services segment.
The company had posted a net profit after taxes, minority interest and share of profit/(loss) of the associates of Rs 27.73 crore for the corresponding period year ago, Dishman Pharmaceuticals said in a BSE filing.
Consolidated total income from operations also rose to Rs 436.55 crore for the quarter under review as against Rs 380.39 crore in the same period last fiscal.
The stock was trading 5.23 per cent up at Rs 239.50 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd